| Theme | Chemotherapy for Gastrointestinal Malignancy | |
|---|---|---|
| Title | Development of New Anti-Cancer Agents and Future Direction of Chemotherapy | |
| Publish Date | 2001/05 | |
| Author | Ichinosuke Hyodo | Department of Internal Medicine, Department of Clinical Research, National Shikoku Cancer Center |
| Author | Hisao Tajiri | Department of Internal Medicine, Department of Clinical Research, National Shikoku Cancer Center |
| Author | Tomohiro Nishina | Department of Internal Medicine, National Shikoku Cancer Center |
| Author | Takashi Terao | Department of Internal Medicine, National Shikoku Cancer Center |
| Author | Shoushi Hirasaki | Department of Internal Medicine, National Shikoku Cancer Center |
| Author | Toshihiko Doi | Department of Internal Medicine, National Shikoku Cancer Center |
| Author | Hisashi Endo | Department of Internal Medicine, National Shikoku Cancer Center |
| Author | Toshikazu Masumoto | Department of Internal Medicine, National Shikoku Cancer Center |
| [ Summary ] | The key drugs in the treatment of gastrointestinal cancer are fluoropyrimidines, platinum derivatives, topoisomerase I inhibitors, gemcitabine and recently taxanes. New cytotoxic (oral topotecan, PK1, JM216, Tomudex, DX-8951f, etc.) and cytostatic (IMC-C225, ZD1839, rhuMAb VEGF, SU5416, Marimastat, etc.) anti-cancer agents were discussed here, from the viewpoint of future clinical development and application. | |